
Albertsons Companies (ACI) Stock Forecast & Price Target
Albertsons Companies (ACI) Analyst Ratings
Bulls say
Albertsons Companies has demonstrated a positive financial trajectory, with net sales revenue increasing 2.08% year-over-year, rising from $79.71 billion to $81.37 billion for the 12 months ending August 2025. The company's ability to grow comp sales by 2.2% is notably supported by strong demand across non-perishables, pharmacy sectors, and robust digital engagement, with digital sales surging 21% in Q3 2025. Additionally, pharmacy sales rose significantly by 19% year-over-year, highlighting increased prescription volumes and integration of health services, which together bolster the company’s overall resilience amidst varying economic conditions.
Bears say
Albertsons Companies has experienced key financial challenges that contribute to a negative outlook, including a decline in gross margin of 50 basis points to 27.4%, exacerbated by a shift in product mix towards lower-margin pharmacy and digital segments. The company also saw a year-over-year decline in Net Operating Profit After Tax (NOPAT) of 3.53%, dropping from $1.93 billion to $1.86 billion, alongside a 2.33% decrease in Economic Operating Cash Flow (EBITDAR), from $6.01 billion to $5.87 billion. Additionally, Return on Capital (ROC) fell from 7.78% to 7.35%, and Economic Profit (EP) experienced a significant decline of 29.28%, indicating deteriorating profitability and economic efficiency within the company.
This aggregate rating is based on analysts' research of Albertsons Companies and is not a guaranteed prediction by Public.com or investment advice.
Albertsons Companies (ACI) Analyst Forecast & Price Prediction
Start investing in Albertsons Companies (ACI)
Order type
Buy in
Order amount
Est. shares
0 shares